Adaptive Biotechnologies (ADPT) Total Debt (2022 - 2026)

Adaptive Biotechnologies has disclosed Total Debt across 5 years of filings, most recently posting $130.6 million for Q1 2026.

• In Q1 2026, Total Debt fell 2.25% year-over-year to $130.6 million; the TTM figure through Mar 2026 stood at $130.6 million (down 2.25% YoY), while the FY2025 annual figure was $131.2 million, down 1.55% from the prior year.
• Total Debt came in at $130.6 million for Q1 2026 at Adaptive Biotechnologies, roughly flat from $131.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $133.6 million in Q2 2025 to a low of $125.4 million in Q4 2022.
• Average Total Debt over 5 years is $131.4 million, with a median of $131.7 million recorded in 2024.
• Year-over-year, Total Debt increased 4.23% in 2023 and declined 2.25% in 2026.
• Over 5 years, Total Debt stood at $125.4 million in 2022, then climbed by 4.23% to $130.7 million in 2023, then increased by 2.0% to $133.3 million in 2024, then decreased by 1.55% to $131.2 million in 2025, then fell by 0.5% to $130.6 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $130.6 million in Q1 2026, $131.2 million in Q4 2025, and $131.8 million in Q3 2025.